Another Lurasidone Setback As Takeda Exits Alliance

This article was originally published in The Pink Sheet Daily

08 May 2015
News

Ian Haydock @ScripIanHaydock ian.haydock@informa.com

Executive Summary

Takeda has ended an alliance with fellow Japanese firm Sumitomo Dainippon for Latuda (lurasidone), dealing the second major blow to the atypical antipsychotic in recent weeks.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
BioPharmaceutical
Regions
Asia Pacific

Japan

Europe
Subjects
Deals
Clinical Trials

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Japan Europe

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS078550

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS078550

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Another Lurasidone Setback As Takeda Exits Alliance

News

Executive Summary

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert